

Cutaneous Abscess at the Pacemaker Implantation Site: Clinical and Therapeutic Considerations

Manuscript Info

Manuscript History

Received: xxxxxxxxxxxxxxxx
Final Accepted: xxxxxxxxxxxxxxxx
Published: xxxxxxxxxxxxxxxx

Key words:-

Cardiac arrhythmias ,CIED infection,
Pacemaker, pocket infection,

Abstract

Infections of cardiac implantable electronic devices (CIEDs) are uncommon but potentially life-threatening. We present the case of an 84-year-old man with a pacemaker, diabetes, and hypertension, who developed a painful, erythematous swelling over the device site. Laboratory workup showed elevated inflammatory markers. He was treated with intravenous antibiotics and underwent pacemaker relocation. Early recognition and complete device management are critical to prevent complications.

Copy Right, IJAR, 2026. All rights reserved.

1
2
3
4
5
6

Introduction:-

7 Cardiac arrhythmias are commonly managed using cardiac pacing systems [1]. With expanding indications, the
8 number of cardiac implantable electronic devices (CIEDs) has grown substantially. Pacemakers remain the most
9 frequently used, typically implanted in the left subclavian region within a subfascial pocket beneath the pectoralis
10 major muscle. Due to their invasive nature, these devices carry risks of peri-procedural and post-procedural
11 complications, including pocket infections. Infections can present in various forms, such as localized abscesses at
12 the device site. Risk factors include diabetes, heart or renal failure, corticosteroid therapy, postoperative hematoma,
13 lack of antibiotic prophylaxis, anticoagulation, prior CIED infection, or generator replacement [2]. Once a CIED
14 infection is confirmed, complete hardware removal is generally recommended to prevent severe or recurrent
15 complications [3].

Observation :

17
18 We report the case of an 84-year-old man with type 2 diabetes mellitus managed with oral antidiabetic agents,
19 complete atrioventricular block with a pacemaker implanted in 2018, hypertension under treatment, and a prior
20 cutaneous infection at the pacemaker site several months earlier. The patient presented with a painful swelling
21 beneath the left clavicle evolving over one month, preceded by high fever, chills, and pronounced fatigue. Fifteen
22 days before admission, he reported a flu-like syndrome.

23 On examination, heart rate was stable at 90 bpm, and auscultation revealed a loud systolic murmur throughout the
24 heart. Dermatological evaluation revealed a poorly demarcated, erythematous, edematous, and pigmented plaque,
25 warm and tender, with overlying skin detachment and palpable fluctuation (Figure 1). The lesion was located in the
26 left subclavicular lateral thoracic region over the pacemaker, while lymph nodes were not enlarged.

27 Laboratory investigations showed hemoglobin 10.3 g/dL, white blood cells 6,270/mm³ with 4,600 neutrophils, C-
28 reactive protein 46 mg/L, creatinine 9 mg/L (clearance 85 mL/min), potassium 4.4 mEq/L, and creatine
29 phosphokinase 113 IU/L. Blood cultures (aerobic and anaerobic) and local aspiration yielded seropurulent fluid
30 (Figure 2), but microbiological cultures were negative, likely due to immediate empirical antibiotic therapy. The
31 patient received intravenous amoxicillin-clavulanate 1 g three times daily and ciprofloxacin 400 mg twice daily,
32 supplemented with sugar-free vitamin C. Pacemaker relocation was subsequently performed to control the infection.

33 **Discussion:**

34 Pacemaker implantation techniques have improved to minimize complications [4]. The risk of infection after
35 pacemaker implantation ranges from 0.5% to 1% in the first 6–12 months, increasing with device complexity [5].
36 Infection rates for implantable cardioverter-defibrillators (ICDs) are approximately 1.7% within six months and up
37 to 9.5% after two years, with even higher rates for cardiac resynchronization therapy (CRT) devices [6,7].
38 Replacements and revisions, particularly in elderly patients with comorbidities, further increase infection risk.

39 Patients with CIED infections typically present with local inflammatory signs—swelling, erythema, warmth—at the
40 device site. Systemic manifestations may include fever >38 °C, chills, night sweats, malaise, and weight loss; septic
41 shock occurs in fewer than 10% of cases [8]. Symptoms and laboratory tests may sometimes be normal, and
42 bacteremia can occur at any time during the device lifespan.

43 Confirmation of CIED infection, whether systemic or localized to the pocket, generally requires complete hardware
44 removal, initiation of antibiotic therapy, and planning for re-implantation. Minor incisional or suture-related
45 abscesses shortly after implantation that do not communicate with the pocket may be managed conservatively with
46 antibiotics and careful follow-up [9]. Prompt and complete treatment is essential to reduce morbidity and mortality.

47 **Conclusion:**

48 To conclude, CIED infections are increasingly frequent and carry a high mortality risk if untreated. Diagnosis can be
49 challenging, and potential involvement of other cardiac structures should be assessed. Definitive management
50 requires complete device removal, which can be safely performed in specialized centers, while re-implantation is not
51 always necessary.

52 **Figure Legends:**

53 Figure 1: Clinical presentation of a poorly demarcated, erythematous, edematous, and pigmented plaque over the left
54 subclavicular region above the pacemaker, warm and tender with overlying skin detachment and palpable
55 fluctuation.

56 Figure 2: Local aspiration of the pacemaker pocket yielding seropurulent fluid.

57 **References :**

58 1- Fu DG. Cardiac arrhythmias: diagnosis, symptoms, and treatments. *Cell Biochem Biophys.*
59 2015;73(2):291-296. doi: 10.1007/s12013-015-0626-4.

60 2- Mulpuru SK, Madhavan M, McLeod CJ, Cha YM, Friedman PA. Cardiac pacemakers: function,
61 troubleshooting, and management: part 1 of a 2-part series. *J Am Coll Cardiol.* 2017;69(2):189-210. doi:
62 10.1016/j.jacc.2016.10.061.

63 3- Datta G: A study on pacemaker pocket infection . *J CardiolCardiovasc Med.* 2020, 5:56-9.
64 10.29328/jccm.1001087

65 4- Clémenty N, Fernandes J, Carion PL, et al. Pacemaker complications and costs: a nationwide economic
66 study. *J Med Econ.* 2019;22(11):1171-1178. doi: 10.1080/13696998.2019.1652186

67 5- Johansen JB, Jørgensen OD, Møller M, Arnsbo P, Mortensen PT, Nielsen JC: Infection after pacemaker
68 implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299
69 consecutive patients. *Eur Heart J* 2011; 32: 991–8.doi: 10.1093/eurheartj/ehq497.

70 6- Prutkin JM, Reynolds MR, Bao H, et al.: Rates of and factors associated with infection in 200 909
71 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry.
72 *Circulation* 2014; 130: 1037–43.doi: 10.1161/CIRCULATIONAHA.114.009081

73 7- Palmisano P, Accogli M, Zaccaria M, et al.: Rate, causes, and impact on patient outcome of implantable
74 device complications requiring surgical revision: large population survey from two centres in Italy. *Europace* 2013;
75 15: 531–40. doi: 10.1093/europace/eus337.

76 8- Rybak-D'Obryn J, Machoń NJ, Lewandowska JA, Owczarczyk-Saczonek A, Placek W. Abscess after
77 cardiac pacemaker implantation: A case report. *Clin Case Rep.* 2023 ;11:e7639. doi: 10.1002/ccr3.7639.

78 9- Cosedis Nielsen J, Gerdes JC, Varma N. Infected cardiac-implantable electronic devices: prevention,
79 diagnosis, and treatment. *Eur Heart J.* 2015 ;36:2484–2490. doi: 10.1093/eurheartj/ehv060.

80
81